Recent advances in developing specific therapies for haemophilia

Author:

Ling Gavin1ORCID,Nathwani Amit C.1,Tuddenham Edward G. D.1

Affiliation:

1. Katherine Dormandy Haemophilia and Thrombosis Centre; Royal Free London NHS Foundation Trust; London UK

Publisher

Wiley

Subject

Hematology

Reference71 articles.

1. Pharmacodynamic data and coagulation biomarkers in persons with hemophilia A (PwHA) with inhibitors: results from the HAVEN 1 Emicizumab (ACE910) Phase 3 study;Adamkewicz;Research and Practice in Thrombosis and Haemostasis,2017

2. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report;Astermark;Haemophilia,2010

3. Inhibitory nanobodies against antithrombin correct thrombin generation and reduce bleeding in FVIII-deficient mice;Ayme;Research and Practice in Thrombosis and Haemostasis,2017

4. Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years;Björkman;European Journal of Clinical Pharmacology,2009

5. Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring;Björkman;Journal of Thrombosis and Haemostasis,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3